WO2009092912A1 - Procede de preparation de composes morphiniques - Google Patents
Procede de preparation de composes morphiniques Download PDFInfo
- Publication number
- WO2009092912A1 WO2009092912A1 PCT/FR2008/001558 FR2008001558W WO2009092912A1 WO 2009092912 A1 WO2009092912 A1 WO 2009092912A1 FR 2008001558 W FR2008001558 W FR 2008001558W WO 2009092912 A1 WO2009092912 A1 WO 2009092912A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- morphine
- unsaturated
- reaction
- naloxone
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
- C07D489/08—Oxygen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B63/00—Purification; Separation; Stabilisation; Use of additives
- C07B63/02—Purification; Separation; Stabilisation; Use of additives by treatment giving rise to a chemical modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
Definitions
- the present invention relates to a process for the preparation of morphine compounds, especially naloxone, with a low content of unsaturated ⁇ - ⁇ compounds. It also relates to the compositions thus obtained.
- Morphine and related compounds such as codeine, hydrocodone, hydromorphone, naloxone, naltrexone, oxycodone and oxymorphone are used as active ingredients in analgesics.
- Naloxone base (CAS No. 465-65-5) is a morphine derivative used as a pharmaceutical active ingredient, particularly for the treatment of overdose: naloxone is administered to move the morphine receptors to stop its action.
- This compound is accessible by total synthesis, but given the complexity of the molecule, the synthesis generally begins with plant extracts, especially poppy, either from the capsule or from the resin (opium ). These extracts usually comprise different structurally close compounds which give rise during the synthesis to the formation of species that are sometimes difficult to separate.
- the morphine compounds it is sought to limit in the morphine compounds the presence of ⁇ - ⁇ unsaturated ketone compounds because of the supposed toxicity of some of them.
- the morphine compounds have a content of ⁇ - ⁇ unsaturated compounds below 100 ppm.
- WO 2006/084389 proposes to reduce the content of unsaturated ⁇ - ⁇ compounds by selective hydrogenation.
- document WO 2006/084412 recommends that the ⁇ -ketonic hydroxyl group be preliminarily converted into a leaving group with acetic anhydride and then hydrogenated selectively.
- the document US 2006/0111383 proposes to acidify the mixture to a pH of less than 6 and to possibly heat it above 55 ° C. before the hydrogenation.
- hydrogenation most often involves the use of catalysts whose total absence in the final product is then very difficult to ensure.
- WO2007 / 062184 proposes the elimination of ⁇ - ⁇ unsaturated electrophilic compounds of oxycodone by reaction with a thiol.
- WO2007 / 103105 also uses a reaction with a thiol to remove unsaturated ⁇ - ⁇ compounds.
- thiol is accompanied by significant odors, and toxicity for most of them. In addition, it must also ensure the absence of thiol in the active product.
- the object of the present invention is to provide a process for the preparation of morphine compounds of high purity, and in particular comprising a low content of unsaturated ⁇ - ⁇ compounds.
- the invention relates to a process for the preparation of morphine compounds with a low content of unsaturated ⁇ - ⁇ compounds comprising the steps of:
- the invention provides a composition comprising at least 99%, preferably at least 99.5% by dry weight of morphine compound or a pharmaceutically acceptable salt thereof and an ⁇ - ⁇ -unsaturated compound in a lower content. at 100 ppm and preferably less than 50 ppm.
- morphine compounds is understood to mean compounds of structure close to morphine, and in particular comprising a phenolic ring. These compounds may differ from morphine in particular by the nature of their substituents or the nature of the bonds. More specifically, these are 3-hydroxymorphinone derivatives corresponding to the following formula (I):
- R1 represents a hydrogen atom or a hydroxyl group
- R 2 represents a hydrogen atom or a (C 1 -C 6 ) alkyl, cyclo (C 3 -C 6 ) alkyl or (C 2 -C 6 ) alkenyl group.
- a (C 1 -C 8) alkyl group a linear or branched saturated aliphatic group containing between 1 and 6 carbon atoms, for example methyl or ethyl groups may be mentioned; propyl, isopropyl, butyl, isobutyl, tertbutyl, pentyl, etc .;
- a cyclo (C 3 -C 6 ) alkyl group a cyclic alkyl group comprising between 3 and 6 carbon atoms.
- cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl groups examples include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl groups;
- a (C 2 -C 6 ) alkenyl group a linear or branched, mono- or poly-unsaturated aliphatic group comprising, for example, one or two ethylenic unsaturations and containing between 2 and 6 carbon atoms.
- the vinyl group Particularly targeted are hydromorphone, naloxone, naltrexone, noroxymorphone, oxymorphone and nalbuphone.
- ⁇ - ⁇ -unsaturated compounds is intended to mean compounds comprising a double bond at position 7 and 8 of the morphine ring conjugated with a ketone at position 6. More precisely, these are 3-hydroxy-derivatives. 7,8-Didehydromorphinone corresponding to the following formula (II):
- R1 and R2 have the same meanings as previously indicated.
- R1 and R2 have the same meanings as previously indicated.
- crude morphine compound is intended to mean a mixture of compounds essentially comprising a morphine compound or a derivative of 3-hydroxymorphinone as defined above and generally an ⁇ , ⁇ -unsaturated compound or 3-hydroxy derivative. , 8 didehydromorphinone as defined above in a smaller amount.
- the ⁇ , ⁇ -unsaturated compound content is generally less than 1% and most often between 0.1% and 0.2% by weight.
- product resulting from the aldolisation reaction is meant the dimer resulting from the reaction of the enolate with the ketone. More specifically, these are bis hydroxy morphinol-morphinone derivatives having the following formula (IV):
- R1 and R2 have the same meanings as previously indicated.
- product resulting from the crotonization reaction is meant the mother resulting from the dehydration reaction of aldol. More specifically, these are bis hydroxy morphinene-morphinone derivatives having the following formula (V):
- R1 and R2 have the same meanings as previously indicated.
- the invention is based on the surprising finding that the content of the morphine compounds can be reduced to ⁇ - ⁇ -unsaturated compounds, especially those having a double bond in position 7 and 8 of the ketone conjugated morphine ring at the 6-position. Michael addition of the hydroxide ion on the double bond.
- the invention relates to a process for the preparation of morphine compounds with a low content of unsaturated ⁇ - ⁇ compounds comprising the steps of:
- the method further comprises the subsequent step of:
- step (i) of the described process is carried out:
- the step (N) is carried out by precipitation, which is advantageously obtained by adding a neutralization agent, in particular an acid.
- Step (iii) is preferably performed at the same time as step (iv).
- the morphine compound is naloxone.
- the unsaturated ⁇ - ⁇ compound is 7,8-didehydronaloxone.
- the process according to the invention makes it possible, by a simple and rapid treatment, involving current and non-toxic reagents, to obtain a morphine compound of very high purity.
- the process makes it possible to lower the presence of unsaturated ⁇ - ⁇ compounds below the regulatory thresholds, and most often below the detection threshold.
- the addition compounds formed are hydrophilic and can therefore be easily removed.
- this elimination takes place during the usual purification, and in particular during the transformation into a pharmaceutically acceptable salt, for example during the hydrochlorination.
- the purification may comprise in particular a filtration step, for example on alumina.
- the method described can therefore be implemented without major modifications of the procedures in place and recorded.
- the process described makes it possible to transform the unsaturated ⁇ - ⁇ unsaturated compounds by a nucleophilic addition reaction called Michael type addition.
- Michael type addition This reaction is well known as such, and is described for example in "Advanced Organic Chemistry” by Smith and March, 5 th Edition, (Chapter 15, p.976, 1022 to 1024).
- the addition takes place on the double bond conjugated to the ketone function.
- the adduct formed is therefore the corresponding hydroxylated saturated compound. These compounds are most often less toxic than ⁇ - ⁇ unsaturated compounds.
- Reaction Scheme 1 illustrates the reaction to the base of the process for the particular example of naloxone.
- Naloxone may contain as ⁇ - ⁇ -unsaturated impurity especially 7.8 didehydronaloxone. This compound is converted by basic treatment to 8-hydroxy naloxone.
- Basic treatment
- the compound formed by the reaction is more hydrophilic and may optionally be readily separated from the morphine compound.
- the compounds formed by the Michael addition reaction are separated during the usual subsequent isolation and purification steps.
- the Michael-type addition reaction proceeds in competition with secondary reactions, in particular the aldolization and crotonization reaction.
- Reaction Scheme 2 illustrates the aldol reaction for the example of naloxone.
- the dimeric product formed is relatively hydrophilic. It is therefore easily separable during subsequent isolation and purification steps.
- naloxone Crotonization of naloxone leads to the corresponding dehydrated compound.
- the reaction is illustrated in Reaction Scheme 3 above for the example of naloxone. It has been established by structural NMR analysis that only the compound with endocyclic unsaturation is formed.
- Crotonization is an irreversible reaction, unlike the aldol reaction, which is in equilibrium with the reverse reaction called retroaldolisation. Furthermore, the compound resulting from the crotonization of the aldol product is not very water-soluble and therefore more difficult to separate from the reaction product.
- an effective means for limiting the crotonization reaction is to limit the formation of aldol, which is the starting material of crotonization.
- the crude morphine compound obtained by these processes generally has a content of ⁇ - ⁇ unsaturated compounds of less than 1%, most often between 0.1% and 0.2% by weight.
- the process according to the invention allows the Michael-type addition reaction on the unsaturated ⁇ - ⁇ compounds present in the crude morphine compound.
- the crude morphine compound is generally dissolved in a suitable solvent, advantageously in aqueous solution. It is preferable that the solution has a concentration between 5 and 25% by weight of crude morphine compound.
- the base used is preferably a strong mineral base, such as alkali and alkaline earth metal hydroxides and in particular sodium or potassium hydroxide.
- the amount of base is preferably in excess relative to the morphine compound employed. Generally, it represents at least 3, or even at least 5 equivalents calculated with respect to the morphine compound.
- the reaction mixture has a pH greater than 13 or even greater than 14.
- a base in concentrated solution will be used. Indeed, the retro-aldolization reaction is favored in a strongly basic medium, which limits the amount of aldol available for crotonization.
- the morphine compound solution is introduced into the base and not vice versa.
- This variant called reverse casting, provides a strongly basic reaction medium at any time.
- the process according to the invention can be carried out in a simple manner and on conventional equipment.
- the morphine compound is brought into contact with a basic medium, preferably with stirring.
- the reaction medium is preferably maintained at a temperature of 20 to 25 ° C.
- the contact time of the reaction mixture is preferably short in order to disadvantage the aldolization. This is not a problem in terms of conversion since the addition reaction of Michael is usually complete in 10 to 40 minutes, and most often in 20 to 30 minutes.
- the reaction medium is neutralized.
- the neutralizing agent will most often be a usual acid, strong or weak, organic or mineral. Particularly preferred are hydrochloric acid, sulfuric acid or acetic acid.
- the morphine compound is neutralized until precipitation. Generally, the morphine product precipitates at neutral to moderately basic pH, for example between pH 8 and 10.
- the solid product is then separated from the reaction mixture by conventional methods, for example by filtration.
- Filtration on a polar medium such as alumina is particularly interesting because it allows affinity retention of the more hydroxylated compounds, especially the aldol products.
- the morphine compound obtained, in the form of a solvent base is then converted into a pharmaceutically acceptable salt, especially hydrochloride, mucate, hydrobromide, stearate, pamoate, napsylate, 2-hydroxy (1, 1, 3, 3-tetramethylbutyl) benzoate, or else 3,5-bis (1,1-dimethylethyl) -2,6-dihydrobenzoate.
- a pharmaceutically acceptable salt especially hydrochloride, mucate, hydrobromide, stearate, pamoate, napsylate, 2-hydroxy (1, 1, 3, 3-tetramethylbutyl) benzoate, or else 3,5-bis (1,1-dimethylethyl) -2,6-dihydrobenzoate.
- This step can be carried out by reaction of the morphine compound obtained with the corresponding acid.
- the base is poorly water soluble, and so a solution of the morphine compound is prepared in a suitable solvent, for example acetone.
- the salt formed is separated, for example by precipitation.
- the salts of the dimeric compounds from the aldolization and crustalization reactions are better soluble in water than the salt of the morphine compound. Their content can therefore be reduced during this step.
- the morphine compound or its salt thus obtained can, if necessary, be further purified according to known methods, for example by recrystallization.
- anhydrous morphine compound by removal of the solvent, especially by drying in an oven.
- the compounds resulting from the reaction and the secondary reactions are thus separated by the subsequent purification steps, without the need for a step specifically provided for this purpose.
- the invention relates to a composition comprising at least 99% by dry weight of morphine compound and an ⁇ - ⁇ -unsaturated compound content of less than 100 ppm.
- the invention provides a composition comprising at least 99%, preferably at least 99.5% by dry weight of morphine compound or a pharmaceutically acceptable salt thereof and an ⁇ - ⁇ -unsaturated compound in a content of less than 100.
- ppm preferably less than 50 ppm and more preferably less than 25 ppm.
- the morphine compounds and their salts easily form solvates, and especially in the form of mono-, di- or trihydrates.
- the contents of these compounds are therefore generally expressed relative to the dry compound, without taking into account the water content or solvents.
- the contents indicated in the following, unless otherwise indicated, are therefore always in relation to the dry compound.
- compositions when the morphine compound is naloxone, its hydrochloride or hydrochloride dihydrate are particularly targeted.
- the unsaturated ⁇ - ⁇ compound is preferably 7,8-didehydronaloxone.
- the composition also contains, in a small amount, compounds resulting from the aldolisation and crotonization reaction.
- the subject of the present invention is in particular a composition comprising at least 99% by dry weight, preferably at least 99.5% by dry weight, of morphine compound or of a pharmaceutically acceptable salt thereof, an unsaturated ⁇ - ⁇ compound. in a content of less than 100 ppm and preferably less than 50 ppm, and further comprising at least one compound derived from the aldolization and crotonization reactions.
- the compounds resulting from the aldolisation reaction and the crotonization reaction are generally present in a content of less than 1000 ppm and in particular less than or equal to 500 ppm in the compositions according to the invention
- the compound resulting from the aldolization reaction is generally present in a content ranging from 20 to 200 ppm and in particular from 50 to 150 ppm.
- the morphine compound when in the composition according to the invention the morphine compound is in salt form, the compound resulting from the crotonization reaction is generally present in a content ranging from 150 to 500 ppm and in particular from 200 to 350 ppm.
- naloxone it is 6'-7-naloxol-naloxone and
- compositions according to the invention comprising a pharmaceutically acceptable salt of morphine compound; in particular a naloxone hydrochloride.
- morphine compounds or their salts are most often solvates, and in particular hydrates.
- Particularly targeted is a composition comprising naloxone hydrochloride dihydrate.
- the present invention relates to a composition
- a composition comprising naloxone hydrochloride dihydrate, 7-8 didehydronaloxone, especially at a content of less than 90 ppm, 6'-7 naloxol naloxone especially in a content ranging from 50 to 150 ppm and 6'-7 'olefin of 6'-7-naloxol-naloxone especially in a content ranging from 200 to 350 ppm.
- the composition will further contain solvent in a corresponding amount.
- the composition may further contain up to 10% by weight of water relative to the total weight of the composition.
- Fig. 1 HPLC analysis result of naloxone base with low content of ⁇ - ⁇ unsaturated compounds obtained in the example
- 2 HPLC analysis result of naloxone hydrochloride with low content of ⁇ - ⁇ unsaturated compounds obtained in the example.
- the medium is then loaded into a dropping funnel and then added dropwise into a three-necked flask containing 36 ml (0.27 mol; 8 eq) of concentrated sodium hydroxide (30%).
- the initial ambient temperature of 21.6 ° C. of the reaction medium reaches, at the end of the casting, 21.5 ° C., the pH of the reaction medium then being 14.4.
- the reaction medium has a temperature of 41.7 ° C. and a pH of 9.
- the medium is cooled to 10.degree. C. and the precipitate is separated by filtration on sintered glass.
- the separated solid product is dried in a ventilated oven at 60 ° C.
- the treated crude base naloxone is isolated with a mass of 15.64 g dry.
- the product obtained at the end of these operations is called "naloxone base treated" in Tables 1 to 4 below.
- the naloxone base obtained is dissolved in acetone and then chlorhydrated by addition of concentrated hydrochloric acid.
- the hydrochloride is precipitated by cooling, filtered and dried.
- the product obtained after these operations is called "pure naloxone HCl" in Tables 1 to 4 below.
- the product obtained is analyzed according to the HPLC method described by the European Pharmacopoeia after the basic treatment, and after hydrochlorination.
- the process according to the invention makes it possible to obtain, by the basic treatment, naloxone with a low content of 7,8-didehydronaloxone.
- the treatment makes it possible to lower the content of 7,8-didehydronaloxone from 0.8% by weight initially to less than 0.03% by weight, and therefore below the detection threshold.
- a more specific HPLC method shows that the content of 7,8-didehydronaloxone, to be less than 100 ppm, has a usual value of 60 to 90 ppm.
- Naloxone thus obtained at this stage meets the regulatory requirements for the content of 7,8-didehydronaloxone.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ585218A NZ585218A (en) | 2007-11-09 | 2008-11-06 | Method for the preparation of morphine compounds |
JP2010532634A JP2011503040A (ja) | 2007-11-09 | 2008-11-06 | モルヒネ化合物の調製方法 |
CA2705251A CA2705251A1 (fr) | 2007-11-09 | 2008-11-06 | Procede de preparation de composes morphiniques |
MX2010005124A MX2010005124A (es) | 2007-11-09 | 2008-11-06 | Procedimiento de preparacion de compuestos morfinicos. |
AU2008348675A AU2008348675A1 (en) | 2007-11-09 | 2008-11-06 | Method for the preparation of morphine compounds |
CN200880115278A CN101868462A (zh) | 2007-11-09 | 2008-11-06 | 制备吗啡化合物的方法 |
EA201070589A EA017287B1 (ru) | 2007-11-09 | 2008-11-06 | Способ получения морфийных соединений |
BRPI0820300-8A BRPI0820300A2 (pt) | 2007-11-09 | 2008-11-06 | Processo de preparo de compostos morfínicos |
EP08871482A EP2231673A1 (fr) | 2007-11-09 | 2008-11-06 | Procede de preparation de composes morphiniques |
US12/774,156 US8455509B2 (en) | 2007-11-09 | 2010-05-05 | Method for the preparation of morphine compounds |
IL205601A IL205601A0 (en) | 2007-11-09 | 2010-05-06 | Method for the preparation of morphine compounds |
ZA2010/03241A ZA201003241B (en) | 2007-11-09 | 2010-05-07 | Method for the preparation of morphine compounds |
MA32893A MA31982B1 (fr) | 2007-11-09 | 2010-06-07 | Procede de preparation de composes morphiniques |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0758923 | 2007-11-09 | ||
FR0758923A FR2923484B1 (fr) | 2007-11-09 | 2007-11-09 | Procede de preparation de composes morphiniques |
US2194908P | 2008-01-18 | 2008-01-18 | |
US61/021,949 | 2008-01-18 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/774,156 Continuation US8455509B2 (en) | 2007-11-09 | 2010-05-05 | Method for the preparation of morphine compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009092912A1 true WO2009092912A1 (fr) | 2009-07-30 |
Family
ID=39099817
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2008/001558 WO2009092912A1 (fr) | 2007-11-09 | 2008-11-06 | Procede de preparation de composes morphiniques |
Country Status (21)
Country | Link |
---|---|
US (1) | US8455509B2 (fr) |
EP (1) | EP2231673A1 (fr) |
JP (1) | JP2011503040A (fr) |
KR (1) | KR20100083815A (fr) |
CN (1) | CN101868462A (fr) |
AR (1) | AR069225A1 (fr) |
AU (1) | AU2008348675A1 (fr) |
BR (1) | BRPI0820300A2 (fr) |
CA (1) | CA2705251A1 (fr) |
CL (1) | CL2008003333A1 (fr) |
EA (1) | EA017287B1 (fr) |
FR (1) | FR2923484B1 (fr) |
IL (1) | IL205601A0 (fr) |
MA (1) | MA31982B1 (fr) |
MX (1) | MX2010005124A (fr) |
NZ (1) | NZ585218A (fr) |
SG (1) | SG186591A1 (fr) |
TW (1) | TW200936592A (fr) |
UY (1) | UY31460A1 (fr) |
WO (1) | WO2009092912A1 (fr) |
ZA (1) | ZA201003241B (fr) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9012468B2 (en) * | 2012-02-08 | 2015-04-21 | Mallinckrodt Llc | One pot process for producing 6-hydroxyl nal-opiate |
US9127008B2 (en) | 2013-03-15 | 2015-09-08 | Johnson Matthey Public Limited Company | Morphine sulfate methanolic solvate, processes for making same and related compositions and methods for treating pain |
US9518062B2 (en) | 2009-07-16 | 2016-12-13 | Mallinckrodt Llc | Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102174049A (zh) * | 2011-03-11 | 2011-09-07 | 山东新华制药股份有限公司 | 一种盐酸纳洛酮成盐的制备工艺 |
CN103408553B (zh) * | 2013-08-20 | 2016-02-03 | 宜昌人福药业有限责任公司 | 一种氢吗啡酮酸式盐的精制工艺 |
CN104230945B (zh) * | 2014-08-23 | 2016-05-18 | 成都天台山制药有限公司 | 盐酸纳洛酮的合成方法 |
US10807995B2 (en) | 2018-07-13 | 2020-10-20 | Alkermes Pharma Ireland Limited | Thienothiophene compounds for long-acting injectable compositions and related methods |
US10799496B2 (en) | 2018-07-13 | 2020-10-13 | Alkermes Pharma Ireland Limited | Naphthylenyl compounds for long-acting injectable compositions and related methods |
US10975099B2 (en) | 2018-11-05 | 2021-04-13 | Alkermes Pharma Ireland Limited | Thiophene compounds for long-acting injectable compositions and related methods |
CN110724155A (zh) * | 2019-11-11 | 2020-01-24 | 北京华素制药股份有限公司 | 一种羟考酮羟醛二聚体的制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006084389A1 (fr) * | 2005-02-11 | 2006-08-17 | Cilag Ltd. | Procede pour epurer des composes de noroxymorphone |
WO2006094672A1 (fr) * | 2005-03-04 | 2006-09-14 | Euro-Celtique S.A. | Procédé de réduction de cétones insaturées alpha et bêta dans des compositions d’opioïdes |
WO2007062184A2 (fr) * | 2005-11-22 | 2007-05-31 | Controlled Chemicals, Inc. | Procédés destinés à réduire les taux d'accepteurs de michael contaminants dans l'oxycodone et d'autres compositions |
WO2007103105A2 (fr) * | 2006-03-02 | 2007-09-13 | Mallinckrodt Inc. | Procédés de préparation de produits à base de morphinan-6-one avec de faibles niveaux de composés de cétones alpha, bêta-insaturées |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0421149D0 (en) | 2004-09-23 | 2004-10-27 | Johnson Matthey Plc | Preparation of oxycodone |
CN104761561A (zh) * | 2006-12-04 | 2015-07-08 | 诺拉姆科有限公司 | 减少羟考酮碱中杂质的方法 |
US7906647B2 (en) * | 2006-12-04 | 2011-03-15 | Noramco, Inc. | Process for preparing oxycodone having reduced levels of 14-hydroxycodeinone |
GB0624880D0 (en) * | 2006-12-14 | 2007-01-24 | Johnson Matthey Plc | Improved method for making analgesics |
-
2007
- 2007-11-09 FR FR0758923A patent/FR2923484B1/fr not_active Expired - Fee Related
-
2008
- 2008-11-06 EP EP08871482A patent/EP2231673A1/fr not_active Withdrawn
- 2008-11-06 BR BRPI0820300-8A patent/BRPI0820300A2/pt not_active IP Right Cessation
- 2008-11-06 CN CN200880115278A patent/CN101868462A/zh active Pending
- 2008-11-06 NZ NZ585218A patent/NZ585218A/xx not_active IP Right Cessation
- 2008-11-06 CA CA2705251A patent/CA2705251A1/fr not_active Abandoned
- 2008-11-06 WO PCT/FR2008/001558 patent/WO2009092912A1/fr active Application Filing
- 2008-11-06 JP JP2010532634A patent/JP2011503040A/ja active Pending
- 2008-11-06 SG SG2012079125A patent/SG186591A1/en unknown
- 2008-11-06 AU AU2008348675A patent/AU2008348675A1/en not_active Abandoned
- 2008-11-06 MX MX2010005124A patent/MX2010005124A/es active IP Right Grant
- 2008-11-06 EA EA201070589A patent/EA017287B1/ru not_active IP Right Cessation
- 2008-11-06 KR KR1020107010076A patent/KR20100083815A/ko not_active Application Discontinuation
- 2008-11-07 UY UY31460A patent/UY31460A1/es not_active Application Discontinuation
- 2008-11-07 TW TW097143241A patent/TW200936592A/zh unknown
- 2008-11-07 CL CL2008003333A patent/CL2008003333A1/es unknown
- 2008-11-07 AR ARP080104878A patent/AR069225A1/es not_active Application Discontinuation
-
2010
- 2010-05-05 US US12/774,156 patent/US8455509B2/en active Active
- 2010-05-06 IL IL205601A patent/IL205601A0/en unknown
- 2010-05-07 ZA ZA2010/03241A patent/ZA201003241B/en unknown
- 2010-06-07 MA MA32893A patent/MA31982B1/fr unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006084389A1 (fr) * | 2005-02-11 | 2006-08-17 | Cilag Ltd. | Procede pour epurer des composes de noroxymorphone |
WO2006094672A1 (fr) * | 2005-03-04 | 2006-09-14 | Euro-Celtique S.A. | Procédé de réduction de cétones insaturées alpha et bêta dans des compositions d’opioïdes |
WO2007062184A2 (fr) * | 2005-11-22 | 2007-05-31 | Controlled Chemicals, Inc. | Procédés destinés à réduire les taux d'accepteurs de michael contaminants dans l'oxycodone et d'autres compositions |
WO2007103105A2 (fr) * | 2006-03-02 | 2007-09-13 | Mallinckrodt Inc. | Procédés de préparation de produits à base de morphinan-6-one avec de faibles niveaux de composés de cétones alpha, bêta-insaturées |
Non-Patent Citations (2)
Title |
---|
KOTICK M P ET AL: "8beta-substituted dihydrocodeinones having heteroatoms in the side chain (I)", JOURNAL OF HETEROCYCLIC CHEMISTRY, HETEROCORPORATION. PROVO, US, vol. 18, no. 5, 1981, pages 1029 - 1033, XP009096588, ISSN: 0022-152X * |
WEISS, ULRICH: "Derivatives of morphine. II. Demethylation of 14-hydroxycodeinone, 14-hydroxymorphinone, and 8,14-dihydroxydihydromorphinone", JOURNAL OF ORGANIC CHEMISTRY , 22, 1505-8 CODEN: JOCEAH; ISSN: 0022-3263, 1957, XP002471976 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9518062B2 (en) | 2009-07-16 | 2016-12-13 | Mallinckrodt Llc | Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers |
US9527858B2 (en) | 2009-07-16 | 2016-12-27 | Mallinckrodt Llc | Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers |
US9012468B2 (en) * | 2012-02-08 | 2015-04-21 | Mallinckrodt Llc | One pot process for producing 6-hydroxyl nal-opiate |
US9127008B2 (en) | 2013-03-15 | 2015-09-08 | Johnson Matthey Public Limited Company | Morphine sulfate methanolic solvate, processes for making same and related compositions and methods for treating pain |
Also Published As
Publication number | Publication date |
---|---|
MX2010005124A (es) | 2010-05-27 |
JP2011503040A (ja) | 2011-01-27 |
KR20100083815A (ko) | 2010-07-22 |
NZ585218A (en) | 2012-08-31 |
MA31982B1 (fr) | 2011-01-03 |
IL205601A0 (en) | 2010-11-30 |
US8455509B2 (en) | 2013-06-04 |
EP2231673A1 (fr) | 2010-09-29 |
ZA201003241B (en) | 2011-08-31 |
BRPI0820300A2 (pt) | 2015-05-19 |
EA017287B1 (ru) | 2012-11-30 |
TW200936592A (en) | 2009-09-01 |
UY31460A1 (es) | 2009-07-17 |
FR2923484A1 (fr) | 2009-05-15 |
US20100256176A1 (en) | 2010-10-07 |
CA2705251A1 (fr) | 2009-07-30 |
FR2923484B1 (fr) | 2012-11-09 |
SG186591A1 (en) | 2013-01-30 |
EA201070589A1 (ru) | 2010-10-29 |
CN101868462A (zh) | 2010-10-20 |
AU2008348675A1 (en) | 2009-07-30 |
AR069225A1 (es) | 2010-01-06 |
CL2008003333A1 (es) | 2010-03-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009092912A1 (fr) | Procede de preparation de composes morphiniques | |
EP1907396B1 (fr) | Procede de preparation de la 4 -amino-4'-demethyl-4-desoxypodophyllotoxine | |
EP0359647A1 (fr) | Procédé de préparation de dérivés de morphinane | |
EP0164290B1 (fr) | Procédé de déalkylation d'alcaloides et intermédiaires | |
EP2376496B1 (fr) | Synthese de morphine-6-glucuronide ou de l'un de ses derives | |
LU83307A1 (fr) | Derives d'adenosine a activite anti-inflammatoire et analgesique,ainsi que des compositions therapeutiques contenant ces derives comme principe actif | |
FR2806724A1 (fr) | Procede pour la preparation de derives 9-deoxo-8a-aza- (8a-alkyl)-8a-homoerythromycine a a partir de la 9-deoxo-9 (z)-hydroxyiminoerythromycine a | |
EP3233779B1 (fr) | Nouveau procede de preparation d'intermediaires de synthese utilisant des produits d'origine naturelle et application des intermedaires obtenus | |
EP0697401B1 (fr) | Synthèse d'esters d'acides mercaptocarboxyliques | |
EP1242439B1 (fr) | Procede pour preparer et isoler la 9-deoxo-9(z)-hydroxyiminoerythromycine a | |
EP3405452A1 (fr) | Procédé de préparation d'analogues de la méthionine | |
EP1468993A1 (fr) | Procédé de préparation de dérivés de l'acide hexahydropyridazine-3-carboxylique | |
CH676598A5 (fr) | ||
EP0418143B1 (fr) | Dérivés dicarboxyliques renfermant un hétérocycle azoté ou oxygéné, leur procédé de préparation et leur application comme médicaments | |
EP0172066B1 (fr) | Procédé de préparation de composés halogénés en alpha d'un groupement électro-attracteur | |
EP0169186B1 (fr) | Nouveaux dérivés de décahydroquinoléinol, leur procédé de préparation et les compositions les contenant | |
FR2491471A1 (fr) | Benzoxazolinones substituees, leur preparation et leur application en therapeutique | |
EP0461972A1 (fr) | Procédé de transformation de N-oxydes d'amines tertiaires en aldéhydes | |
FR2554816A1 (fr) | Nouveau derive de la nororipavine presentant a la fois une activite agoniste et antagoniste des recepteurs morphiniques | |
EP0100717A1 (fr) | Procédé de synthèse d'alphaalkyl amino aldéhydes | |
WO2005105730A2 (fr) | Procede de preparation d'un alcool a partir d'un compose halogenoaromatique et d'un aldehyde. | |
FR3055626A1 (fr) | Procede de synthese d'un compose steroide comprenant un substituant n-methylaniline en position 11 | |
EP0065909A1 (fr) | ((Pipéridyl-4)-2 alkyl-1 éthyl)-3 indoles et leur utilisation comme médicaments | |
FR2667069A1 (fr) | Nouveaux anhydrides d'alditylamines et procedes pour les preparer. | |
FR2795413A1 (fr) | Procede de production d'hexahydrothieno[3,4-d]imidazole-2,4 -diones |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200880115278.6 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08871482 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: DZP2010000225 Country of ref document: DZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12010500997 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 205601 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 20107010076 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 585218 Country of ref document: NZ Ref document number: 2705251 Country of ref document: CA Ref document number: 2010532634 Country of ref document: JP Ref document number: 10054918 Country of ref document: CO Ref document number: 1628/KOLNP/2010 Country of ref document: IN Ref document number: MX/A/2010/005124 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008348675 Country of ref document: AU |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008871482 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2008348675 Country of ref document: AU Date of ref document: 20081106 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201070589 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PI 2010002088 Country of ref document: MY |
|
ENP | Entry into the national phase |
Ref document number: PI0820300 Country of ref document: BR Kind code of ref document: A2 Effective date: 20100507 |